Timur Ivannikov
Stock Analyst at Cantor Fitzgerald
(1.02)
# 3,731
Out of 4,944 analysts
10
Total ratings
62.5%
Success rate
-11.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Timur Ivannikov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Reiterates: Overweight | $8 | $2.00 | +300.00% | 1 | Jun 27, 2025 | |
| PHVS Pharvaris | Maintains: Overweight | $28 → $25 | $21.49 | +16.36% | 1 | May 14, 2025 | |
| ATXS Astria Therapeutics | Reiterates: Overweight | $47 | $7.03 | +568.56% | 1 | May 14, 2025 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $5 | $1.94 | +157.73% | 2 | Mar 7, 2023 | |
| ANAB AnaptysBio | Downgrades: Market Perform | n/a | $20.18 | - | 1 | Jan 6, 2023 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $22 | $3.10 | +610.82% | 1 | Jul 8, 2022 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $112 → $114 | $24.53 | +364.74% | 1 | Mar 1, 2022 | |
| CBIO Crescent Biopharma | Downgrades: Market Perform | n/a | $13.52 | - | 2 | Nov 15, 2021 |
ProQR Therapeutics
Jun 27, 2025
Reiterates: Overweight
Price Target: $8
Current: $2.00
Upside: +300.00%
Pharvaris
May 14, 2025
Maintains: Overweight
Price Target: $28 → $25
Current: $21.49
Upside: +16.36%
Astria Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $47
Current: $7.03
Upside: +568.56%
Gossamer Bio
Mar 7, 2023
Downgrades: Market Perform
Price Target: $5
Current: $1.94
Upside: +157.73%
AnaptysBio
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $20.18
Upside: -
Rocket Pharmaceuticals
Jul 8, 2022
Initiates: Outperform
Price Target: $22
Current: $3.10
Upside: +610.82%
Apellis Pharmaceuticals
Mar 1, 2022
Maintains: Strong Buy
Price Target: $112 → $114
Current: $24.53
Upside: +364.74%
Crescent Biopharma
Nov 15, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $13.52
Upside: -